Neurocrine Biosciences | NBIX - Market Capitalization


Neurocrine Biosciences reported $15.14B in Market Capitalization this September of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
AbbVie USD 444.6B 59.91B Jun/2026
Acadia Pharmaceuticals USD 4.33B 537M Jun/2026
ALKERMES USD 8.73B 2.85B Jun/2026
Alnylam Pharmaceuticals USD 40.19B 3.96B Jun/2026
Amgen USD 195.44B 5.55B Jun/2026
Biogen USD 31.9B 5B Jun/2026
BioMarin Pharmaceutical USD 11.06B 196M Jun/2026
Cytokinetics USD 11.55B 3.36B Jun/2026
Enanta Pharmaceuticals USD 122M 98M Dec/2024
Exelixis USD 13.54B 2.65B Jun/2026
Gilead Sciences USD 156.86B 16.13B Jun/2026
Halozyme Therapeutics USD 9.28B 1.63B Jun/2026
Incyte USD 22.65B 3.92B Jun/2026
Ionis Pharmaceuticals USD 13.1B 642M Jun/2026
Nektar Therapeutics USD 2.12B 1.26B Mar/2026
Neurocrine Biosciences USD 16.95B 3.7B Jun/2026
Pfizer USD 138.44B 15.37B Jun/2026
Prothena USD 516M 2M Mar/2026
Regeneron Pharmaceuticals USD 65.37B 16.31B Jun/2026
Repligen USD 7.7B 1.05B Jun/2026
Sarepta Therapeutics USD 1.9B 388M Jun/2026
Teva Pharmaceutical Industries USD 114.54B 80.27B Jun/2026
Ultragenyx Pharmaceutical USD 3.29B 1.23B Jun/2026
Vertex Pharmaceuticals USD 126.07B 12.49B Jun/2026